期刊文献+

IL-18基因修饰小鼠CT26结肠癌细胞体内外生物学特性 被引量:1

The biological characteristics of IL-18 gene-modified murine colorectal adenocarcinoma cell CT26 in vivo and in vitro
下载PDF
导出
摘要 目的 观察腺病毒介导IL 18基因修饰的小鼠CT2 6结肠癌细胞体内外的生物学特性。方法 采用ELISA法检测细胞因子 ,MTT法检测细胞的增殖反应能力 ,51Cr释放法检测脾细胞的NK活性及CTL杀伤活性。结果 IL 18基因修饰的CT2 6细胞能够在转染后 4小时即可分泌IL 18,4 8小时达到高峰 ,96小时后开始下降。IL 18基因转染对CT2 6在体外培养过程中的增殖与形态没有明显的影响。IL 18基因修饰的CT2 6细胞与野生型的CT2 6细胞和LacZ转染的CT2 6细胞相比 ,在体内的致瘤性明显降低 ,平均生存期延长。IL 18基因修饰的CT2 6细胞在体内的抗肿瘤免疫反应与IL 18活化NK细胞和CTL细胞的杀伤活性有关。结论 IL 18基因修饰的肿瘤细胞能够激发机体的抗肿瘤免疫反应 ,但不足以完全抑制肿瘤细胞的生长 ,还需要与其他因素联合才能够有效地清除肿瘤细胞。 Objective: To observe the biological characteristics of adenovirus-mediated IL-18 gene-modified murine colorectal adenocarcinoma cell CT26 in vivo and in vitro. Methods: The cytokines were assayed by ELISA. Proliferation of the cells was determined by MTT. The cytotoxicity of NK and CTL was detected by 4h 51 Cr releasing assay. Results: The levels of IL-18 could be detected at 4h after CT26 were transfected by IL-18, reached the peak at the 48h, maintained for 96h, and then went down. The morphology and proliferation of IL-18 gene-modified CT26 cells showed no difference from those of wild-type CT26 cells. The tumorigenicity of the IL-18 gene-modified CT26 cells was obviously decreased and the mean survival time was obviously longer compared with that of the wild-type group or the LacZ-transfected CT26 cells. The antitumor immunity of the mice induced by the IL-18 gene-modified CT26 cells was consistent with the elevation of the activity of NK cells and the cytotoxicity of CTL. Conclusion: IL-18 gene-modified tumor cells can induce the antitumor immune responses incompletely, but only inhibit the growth of tumor cells ,thus other factors are reguired for effective antitumor response.
机构地区 泰山医学院
出处 《泰山医学院学报》 CAS 2004年第1期12-14,共3页 Journal of Taishan Medical College
关键词 白细胞介素18 基因疗法 结肠癌细胞 interleukin-18 gene therapy adenocarcinoma cell
  • 引文网络
  • 相关文献

参考文献8

  • 1Tominaga K,Yoshimoto T,Torigue K,et al.IL-12 synergizeswith IL-18 or IL-1heta for IFN-gamma production from human Tcells[J].Int Immunol,2000,12:151-160.
  • 2TakedaK,TsutsuiH,YoshimotoT,etal.DefectiveNKcellactivity and Th1 response in IL-18-deficient mice[J].Immunity,1998,8: 383-390.
  • 3宋文刚,陈宪锐,李雅林,徐英萍,吴聪,秦庆亮.IL-18基因修饰的DC肿瘤融合瘤苗的抗肿瘤效应[J].第四军医大学学报,2003,24(24):2227-2230. 被引量:5
  • 4Okamura H,Kashiwamura S,Tsutsui H,et al.Regulation of interferon-garnma production by IL-12 and IL-18[J].Curr OpinImmunol,1998,10: 259-264.
  • 5宋文刚,曲迅,陈宪锐,李雅林,吴聪,秦庆亮.腺病毒介导的AFP基因修饰树突状细胞的体外生物学特性[J].中国肿瘤生物治疗杂志,2003,10(4):269-273. 被引量:6
  • 6Lauwerys BR,Garot N,Renanld JC,et al.Cytokine productionand killer activ ity of NK/T-NK cells derived with IL-2,IL-15,or the combination of IL-12 and IL-18[J].J Immunol,2000,165: 1847-1853.
  • 7Hashimoto W,Osaki T,Okamura H,et al.Differential antitumor effects of administration of recombinant IL-18 or recombinantIL-12 are mediated primarily byFas-Fas ligand- and perforin-induced tumor apoptosis,respectively[J ].J Immunol,1999,163:583-589.
  • 8Golab J.Interleukin 18-interferon gamma inducing factor-a novelplayer in tumour immunotherapy? [J].Cytokine,2000,12: 332-338.

二级参考文献5

共引文献8

同被引文献15

引证文献1

二级引证文献13

;
使用帮助 返回顶部